Annual report pursuant to Section 13 and 15(d)

Development Award (Details Narrative)

v3.7.0.1
Development Award (Details Narrative)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2016
USD ($)
Apr. 20, 2015
USD ($)
Installments
Nov. 30, 2015
USD ($)
May 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Development Award [Line Items]            
Grants receivable         $ 1,000,000
Deferred revenue       $ 1,250,000   4,500,000
Cystic Fibrosis Foundation Therapeutics Inc [Member]            
Development Award [Line Items]            
Amount received upon execution of award agreement $ 1,000,000   $ 1,250,000 $ 1,250,000 $ 1,250,000 500,000
Deferred revenue           $ 500,000
Oral Anti-inflammatory Drug [Member] | Cystic Fibrosis Foundation Therapeutics Inc [Member]            
Development Award [Line Items]            
Amount received upon execution of award agreement   $ 4,500,000        
Oral Anti-inflammatory Drug [Member] | Maximum [Member]            
Development Award [Line Items]            
Development award received   $ 5,000,000        
JBT-101 [Member]            
Development Award [Line Items]            
Percentage of royalty over receivables under agreement   5.00%        
Number of installments | Installments   3        
Royalty payment, sales target   $ 500,000,000        
Payment due period after the first commercial sale   90 days        
JBT-101 [Member] | Upon Transfer Sale Or Licensing [Member]            
Development Award [Line Items]            
Royalty payable   $ 15,000,000        
JBT-101 [Member] | Maximum [Member] | Upon Commercialization Of The Product [Member]            
Development Award [Line Items]            
Royalty payable   25,000,000        
JBT-101 [Member] | Maximum [Member] | Upon Reaching The Sales Target [Member]            
Development Award [Line Items]            
Royalty payable   $ 5,000,000